Bayer's Off-Label Yaz Marketing Violated FCA: Watchdog

By Sindhu Sundar · December 14, 2011, 4:57 PM EST

A pharmaceutical company watchdog accused Bayer Schering Pharma AG of marketing its Yasmin and Yaz contraceptives for unapproved purposes and causing doctors to seek Medicaid reimbursements for off-label prescriptions of those...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

USA v. Bayer Schering Pharma AG, et al.,

Case Number

1:10-cv-00669

Court

Texas Eastern

Nature of Suit

Other Statutory Actions

Date Filed

October 22, 2010